糖化血红蛋白分析仪 摘要 ： 近日，四川大学发布多批政府采购意向，仪器信息网特对其中的仪器设备品目进行梳理，统计出32项仪器设备采购意向，预 算总额达8845万元。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 近日， 四川大学发布 32 项仪器设备采购意向，预算总额达 8845万 元，涉及 X射线残余应力分析仪、全自动化学 发光免疫分析、全自动血培养仪、全自动血液细胞分析仪、特定蛋白免疫分析仪、糖化血红蛋白分析仪、 长周期大地 测深仪、高水头冲击式机组磨蚀实验系统、 白光干涉轮廓仪 、全身表面污染快速检测仪、植物活体成像系统等，预计 采购时间为202 5 年 6月~2026年1 月。 部分采购仪器简介： X射线残余应力分析仪 X 射 线 残 余 应 力 分 析 仪 利 用 X 射 线 衍 射 原 理 无 损 测 量 材 料 表 层 晶 格 应 变 ， 通 过 布 拉 格 角 位 移 计 算 残 余 应 力 值 （ 常 采 用 s in²ψ法），适用于金属、陶瓷、复合材料等晶体材料。其核心应用包括：航空航天领域、机械制造、焊接工艺优化、 ...

Core Viewpoint - The article highlights the significant growth potential of Mindray Medical's animal healthcare segment, driven by increasing pet ownership and spending, as well as the company's strategic investments and product development in this area [5][8][10]. Group 1: Company Developments - Mindray Medical is planning a secondary IPO in Hong Kong, aiming to raise at least $1 billion (approximately 7.8 billion HKD) [3]. - The company has established a global headquarters for animal healthcare in Longhua, Shenzhen, with a total investment of 1.774 billion RMB, expected to generate an annual output value exceeding 12 billion RMB [2][7]. - The company reported a projected revenue of 36.726 billion RMB and a net profit of 11.668 billion RMB for 2024, positioning it as one of the largest mainland companies seeking a secondary listing in Hong Kong [5]. Group 2: Market Potential - The animal healthcare market is experiencing rapid growth, with the Chinese pet economy projected to reach 592.8 billion RMB in 2023, growing at a rate of 20.1%, and expected to reach 1.15 trillion RMB by 2028 [10]. - The increase in pet ownership is attributed to demographic changes such as aging populations, declining birth rates, and a rise in single-person households [5][10]. Group 3: Product Development and Strategy - Mindray Medical has leveraged its expertise in human medical devices to accelerate the development of animal healthcare products, resulting in a product range that includes imaging, diagnostics, and life support systems for pets [7][8]. - The company has launched several new animal-specific medical devices, including anesthesia machines and diagnostic analyzers, with international animal healthcare business growth exceeding 30% in the first three quarters of 2024 [7][8]. - The international market now accounts for nearly 80% of the company's animal healthcare revenue, indicating strong demand and growth potential [8].